Residual cancer burden in locally advanced breast cancer: a superior tool by Nahleh, Z. et al.
NAHLEH et al.
271 271 271 271 271
CURRENT ONCOLOGY—VOLUME 15, NUMBER 6
MEDICAL ONCOLOGY
Copyright © 2008 Multimed Inc.
ABSTRACT
Objectives
Locally advanced breast cancer (LABC) poses a diffi-
cult clinical challenge with an overall poor long-term
prognosis. The strength of the association between tu-
mour characteristics, treatment response, and outcome
is not well defined. In the present study, we attempted
to gain further insight into LABC by reviewing tumour
characteristics of patients treated with neoadjuvant
chemotherapy and by studying the association of those
characteristics with outcome. We calculated the re-
sidual cancer burden (RCB) score obtained at surgery
and attempted to study its correlation with event-free
survival (EFS) and overall survival (OS).
Methods
We studied patients diagnosed primarily with LABC (n =
45). Pathologic and clinical responses were determined.
Pathology slides were reviewed.
Results
Of the 45 study patients, 9% had stage IIB disease; 29%,
stage IIIA; 51%, stage IIIB; and 11%, stage IIIC. Inflam-
matory breast cancer (IBC) was found in 16%.
Pathologic complete response (pCR) was achieved in
22% of all patients. None of the patients with IBC
achieved pCR. Patients with estrogen receptor–negative
(ER–)/progesterone receptor–negative (PR–) tumours
were more likely to achieve pCR than were those with
ER+/PR+ tumours. Among patients with tumours that
overexpressed human epidermal growth factor receptor
2 (HER2/neu), 17% achieved pCR as compared with 25%
of patients with non-overexpressing tumours; only 1
patient had received trastuzumab. The RCB scores were
calculated in 32 patients and ranged between 0 and 4.6.
Conclusions
The present study examined practical issues related to
the classification and management of LABC and IBC.
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The RCB, defined from routine pathology materials, was
easily quantifiable. It appears to be a better predictor
than pCR of outcome following neoadjuvant chemo-
therapy in LABC. Higher RCB scores were associated
with lower EFS and a lower rate of OS. A continual
quest for reliable predictive and correlative prognostic
markers, and for better surrogate endpoints for outcome,
is essential to advance our understanding of LABC and
to improve treatment outcomes.
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1. INTRODUCTION
Since the late 1970s, tremendous progress has been
achieved in the understanding and management of
breast cancer. However, locally advanced breast can-
cer (LABC) remains a difficult clinical challenge, with
a long-term survival rate of less than 50% 1. Treatment
of LABC uses a multimodality approach involving
chemotherapy, surgery, and radiation therapy 2. The
optimal neoadjuvant chemotherapeutic regimen for
LABC continues to evolve. The aim of neoadjuvant
chemotherapy is to decrease tumour bulk and ideally
to achieve complete clinical and pathologic responses.
Pathologic complete response (pCR) has been
viewed as a reliable primary endpoint for outcome and
survival following neoadjuvant chemotherapy for breast
cancer 3,4. However, residual disease may encompass
a range of pathologic responses likely encompassing a
variety of prognostic groups from near-complete re-
sponse to resistance. Therefore, additional surrogate
endpoints for outcome and survival are needed. Also,
many of the classic biologic predictive and prognostic
factors such as hormone receptors and tumour grade
may have implications that are different in LABC than
in earlier stages of the disease 5–9. To advance our
understanding of this disease, identification of reliable
markers that would lead to better disease classifica-
tion and improved treatment outcomes is desirable.
However, few trials studying primary (preoperative)RESIDUAL CANCER BURDEN AND LOCALLY ADVANCED BREAST CANCER
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chemotherapy have focused exclusively on patients
with locally advanced disease.
In the present observational study, we attempted
to gain further insight into LABC by reviewing tumour
characteristics in patients treated with neoadjuvant
chemotherapy at a single institution, and by studying
the association of those tumour characteristics with
outcome. We were specifically interested in deter-
mining the practicality of calculating the residual can-
cer burden (RCB) scores obtained at surgery and in
studying the correlation of those scores with event-
free survival (EFS) and overall survival (OS) as com-
pared with pCR.
The RCB index was proposed by Symmans et al. 10
as a determinant of the extent of residual disease in
the post-treatment surgical resection specimen of pa-
tients with breast cancer who received preoperative
chemotherapy. The RCB index was found to be an im-
provement over currently used risk factors for the pre-
diction of distant relapse after neoadjuvant
chemotherapy. If independently validated, the RCB in-
dex is suggested to provide an accurate surrogate
endpoint for patient survival.
The RCB index is determined from
￿ the bi-dimensional diameters of the primary tumour
bed in the resection specimen (d1 and d2),
￿ the proportion of the primary tumour bed that con-
tains invasive carcinoma (fin),
￿ the number of axillary lymph nodes containing
metastatic carcinoma (LN), and
￿ the diameter of the largest metastasis in an axil-
lary lymph node (dmet).
Largest bi-dimensional measurements of the re-
sidual primary tumour bed are recorded from the mac-
roscopic description and are combined as follows:
dprime = (d1d2)1/2.          [1]
The proportion of invasive carcinoma (finv) within
the cross-sectional area of the primary tumour bed is
estimated from the overall percentage area of carci-
noma (%CA) and is then corrected for the component
of in situ carcinoma (%CIS):
finv = [1 – (%CIS / 100)] × (%CA / 100).         [2]
Symmans et al. calculated RCB indexes based on a
review of patients who completed neoadjuvant chemo-
therapy for invasive breast carcinoma (T1–3, N0–1,
M0) at the M.D. Anderson Cancer Center 10. We re-
viewed pathology slides and reports from 432 patients
in two completed neoadjuvant trials:
￿ Fluorouracil, doxorubicin, and cyclophosphamide
(FAC) in 189 patients
￿ Paclitaxel followed by FAC (T/FAC) in 243 patients.
The RCB was calculated as an index that com-
bines pathology measurements of the primary tumour
(size and cellularity) and nodal metastases (number
and size). Four RCB categories [RCB-0 (pCR) to RCB-
3 (chemoresistant)] and post-treatment revised
American Joint Committee on Cancer (AJCC) stage
(0–III) for prediction of distant relapse-free survival
(DRFS) were compared in multivariate Cox regres-
sion analyses stratified by estrogen receptor status
(ER) status.
The RCB was found to be a continuous predictor
of DRFS and to predict relapse more strongly than AJCC
stage did. In univariate Cox regression analyses, the
four parameters of residual tumour (dprim, finv, LN,
and dmet) were individually associated with significantly
higher risk of distant relapse (p < 0.001) after T/FAC
chemotherapy. They maintained significance as inde-
pendent predictors in the main-effects multivariate Cox
regression model. Patients had an almost-doubled re-
lapse risk for each unit of increase in the RCB index
[hazard ratio (HR): 1.94; 95% confidence interval (CI):
1.47 to 2.55; p < 0.001]. When the RCB index was in-
cluded in a multivariate Cox regression model that in-
cluded clinical and treatment covariates, the overall
predictive power of the model was significantly im-
proved (p < 0.001), and the RCB index was significantly
associated with the risk of disease recurrence (HR: 2.50;
95% CI: 1.70 to 3.69; p < 0.001).
2. PATIENTS AND METHODS
2.1 Selection Procedures
After obtaining approval from the University of
Cincinnati institutional review board, we conducted a
retrospective chart review of the breast oncology da-
tabase and reviewed the medical records of patients
who received neoadjuvant chemotherapy at the Uni-
versity of Cincinnati between January 1, 2001, and
December 31, 2005. We included consecutive patients
diagnosed primarily with inoperable LABC staged as
IIB, IIIA (T0–N2; T1/2–N2; T3–N1/2), IIIB (T4, N0–
2), or IIIC disease (any T, N3). Patients with inflam-
matory breast cancer (IBC) were included. We
excluded patients diagnosed with operable tumours
staged as I, IIA, and IIB, even if they received
neoadjuvant chemotherapy. Patients with stage IV dis-
ease were also excluded.
Initially, we identified 50 patients; 5 were later
excluded when found to have metastatic disease on
staging workup. We evaluated 45 patients. Tumour and
patient characteristics were reviewed (Table I). Patients
were divided into 4 treatment groups based on their
neoadjuvant chemotherapy regimens:
￿ Anthracycline (doxorubicin or epirubicin) plus
taxane (paclitaxel or docetaxel)
￿ Anthracycline only
￿ Single-agent taxaneNAHLEH et al.
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￿ Other regimens [cyclophosphamide, methotrexate,
and 5-fluorouracil (CMF), capecitabine, and so on]
Treatment with trastuzumab was also noted.
2.2 Tumour Response
Clinical response was recorded before each chemo-
therapy cycle and before surgery. No clinical evidence
of palpable tumour in the breast and axillary lymph
nodes was defined as a clinical complete response
(cCR), reduction in total tumour size of 50% or more
was graded as a clinical partial response (cPR). An
increase in total tumour size of more than 50% or the
appearance of new suspicious ipsilateral axillary ad-
enopathy was considered progressive disease. Tumours
that did not meet the criteria for objective response or
progression were considered stable disease.
Pathologic response was determined at surgery. A
pCR was defined as no invasive tumour in breast or
axillary lymph nodes. Complete response in breast, but
residual disease in lymph nodes was designated RDLN;
residual disease in breast, but no disease in lymph nodes
was designated RDB; and residual disease in both was
designated RDBLN.
2.3 Calculation of Residual Cancer Burden
Pathology slides for 32 of the 45 patients were avail-
able. The characteristics of these 32 patients were very
similar to those of the whole group (Table II). The slides
were retrieved, reviewed, and analyzed by our patholo-
gist (VS) for various parameters that are required to
calculate RCB 10, including
￿ the largest two dimensions (in millimetres) of the
residual tumour bed in the breast (largest tumour
bed if multicentric disease).
￿ histologic mapping of the entire largest cross-sec-
tional area of the residual tumour bed, with spe-
cific identification of the relevant slides in the
pathology report.
￿ histologic assessment of the percentage of the tu-
mour bed area that contains carcinoma (all carci-
noma—that is, invasive and in situ), selected as
one of 0%, 1%, 5%, 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, or 90%.
￿ histologic estimate of the percentage of the carci-
noma in the tumour bed that is in situ, selected as
one of 0%, 1%, 5%, 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, or 90%.
￿ number of positive (metastatic) lymph nodes.
￿ largest diameter (in millimetres) of the largest nodal
metastasis.
These variables were entered into the M.D.
Anderson Residual Cancer Burden Calculator (found
online at www3.mdanderson.org/app/medcalc/
index.cfm?pagename=jsconvert3).
TABLE I   Patient characteristics
 Characteristic % (n)
Race
White 40 (18)
Black 60 (27)
Stage
IIB 9 (4)
IIIA 29 (13)
IIIB 51 (23)
IIIC 11 (5)
Histology
Ductal 75 (34)
Lobular 9 (4)
Inflammatory 16 (7)
Hormone receptor
ER+/PR+ 18 (8)
ER+/PR– 27 (12)
ER–/PR+ 2 (1)
ER–/PR– 53 (24)
HER2/neu
Positive 27 (12)
Negative 73 (33)
ER = estrogen receptor; PR = progesterone receptor; HER2/neu =
human epidermal growth factor 2.
TABLE II Patient characteristics of the study patients and of the
whole group
   Characteristic Study All
patients patients
Patients (n)3 2 4 5
Race (%)
White 38 40
Black 62 60
Stage (%)
IIB 12 9
IIIA 19 29
IIIB 53 51
IIIC 16 11
Histology (%)
Ductal 72 75
Lobular 6 9
Inflammatory 22 16
Hormone receptor (%)
ER+/PR+1 9 1 8
ER+/PR–2 5 2 7
ER–/PR+3 2
ER–/PR–5 3 5 3
HER2/neu (%)
Positive 28 27
Negative 72 73
ER = estrogen receptor; PR = progesterone receptor; HER2/neu =
human epidermal growth factor 2.RESIDUAL CANCER BURDEN AND LOCALLY ADVANCED BREAST CANCER
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2.4 Statistics
Data were entered and analyzed using SPSS biosta-
tistical software package (SPSS, Chicago, IL, U.S.A.),
version 10.0.05. The study aimed primarily to evaluate
the feasibility of RCB calculation from standard pathol-
ogy specimens. It also aimed to study the association
of RCB and pCR with EFS, defined as time to breast
cancer recurrence, itself defined as local lymph node
or breast recurrence, metastasis to other sites, second
primary breast cancer, or any death. Analyses of OS
were also performed; OS included all deaths whether
they were breast cancer–related or not. Patient and dis-
ease characteristics between the different groups were
compared using simple log-rank tests and Cox propor-
tional hazards models. The EFS was considered in a
multivariable setting with Cox proportional hazards
models. Race, hormone receptor status [ER+/proges-
terone receptor positive (PR+), ER+/PR–, ER–/PR+, or
ER–/PR–], chemotherapy (anthracycline, anthracycline
and taxane, taxane, others, and trastuzumab), stage (IIB,
IIIA, IIIB, IIIC, and inflammatory), and human epider-
mal growth factor receptor 2 (HER2/neu) were included
in the multivariable model. The OS and EFS were esti-
mated using the Kaplan–Meier product-limit method.
The two-sided log-rank test was used to compare sur-
vival between pCR and RCB.
3. RESULTS
3.1 Patient Characteristics and Treatment
The median age of the 45 patients in the study was 51
years; 40% (n = 18) were white, and 60% (n = 27)
were black. Stages were distributed as follows: 9%
stage IIB, 29% stage IIIA, 51% stage IIIB, and 11%
stage IIIC. Tumour types were 75% invasive ductal,
9% invasive lobular, and 16% IBC. In 47% of patients,
tumours were ER+ or PR+, distributed as follows: 18%
ER+/PR+, 27% ER+/PR–, 2% ER–/PR+, and 53% ER–/
PR–. Tumours positive for HER2/neu, defined as im-
munohistochemical staining of 3+ or a fluorescent in-
situ hybridization ratio above 2.2 for the HER2/neu
gene to chromosome 17, were identified in 27% of
patients. Neoadjuvant chemotherapy regimens in-
cluded doxorubicin or epirubicin plus taxane
(paclitaxel or docetaxel), 80%; anthracycline-only,
10%; single-agent taxane, 4%; and other regimens (2
CMF, 1 capecitabine), 6%. One patient with HER2/
neu-positive disease received trastuzumab in combi-
nation with chemotherapy.
3.2 Principal Outcomes
Table III shows responses to neoadjuvant chemotherapy.
Clinical responses were distributed as follows: 55% (n
= 25) achieved cCR; 38%, cPR; 4%, stable disease; and
2%, progressive disease. Pathologically, pCR was
achieved in 22% (n = 10) of all patients. Among those
patients, 7% had RDLN; 24%, RDB; and 47%, RDBLN.
None of the patients with IBC achieved pCR. Among
patients with ER+ or PR+ tumours, 19% achieved pCR,
as compared with 25% of patients with ER–/PR– tu-
mours. Among patients with HER2/neu-positive tu-
mours, 17% achieved pCR as compared with 25%
patients whose tumours were HER2/neu-negative.
Among all patients who achieved cCR, only 36%
achieved pCR. In patients who achieved pCR, OS and
EFS were not yet reached at the study duration, as com-
pared with 5.7 years and 19 months respectively for
patients who did not achieve pCR (Figures 1 and 2).
Patients who achieved pCR had the best EFS; however,
patients with residual disease in breast and lymph nodes
appeared to have the worst outcomes (Figure 3).
Pathology slides for 32 patients were available for
examination and calculation of RCB. The characteristics
TABLE III   Clinical and pathologic response after neoadjuvant
chemotherapy
Response % (n)
Clinical
Complete response 55 (25)
Partial response 39 (17)
Stable disease 4 (2)
Progressive disease 2 (1)
Pathologic
Complete response 22 (10)
Residual disease in lymph nodes 7(3)
Residual disease in breast 24 (11)
Residual disease in nodes and breast 47 (21)
FIGURE 1   Event-free survival (EFS) by pathologic complete response
(pCR vs. No pCR) to neoadjuvant chemotherapy in locally advanced
breast cancer.NAHLEH et al.
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of these patients were comparable to those of the study
population (Table II). The resulting RCB indexes ranged
between 0 and 4.6. In 22% of patients (n = 7) the RCB
index was 0; in 19% (n = 6), it was 1 < RCB < 2; in 10%
(n = 3), it was 2 < RCB < 3; in 25% (n = 8), it was 3 <
RCB < 4; and in 25%(n = 8), it was >4. In univariate
Cox regression analysis, RCB correlated with EFS (HR:
1.57; 95% CI: 1.04 to 2.38; p = 0.018) and with OS (HR:
1.74; 95% CI: 0.91 to 3.32; p = 0.09). On the other hand,
pCR did not seem to correlate with either EFS (HR: 0.24;
95% CI: 1.86 to 2.38; p = 0.172) or OS (HR: 0.03; 95%
CI: 0 to 89; p = 0.40). In multivariate Cox regression
analysis, RCB was noted to be an independent predic-
tive variable for EFS (HR: 1.59; 95% CI: 1.04 to 2.43; p =
0.033), but pCR was not (HR: 0.90; 95% CI: 0.52 to 1.57;
p = 0.7).
4. DISCUSSION
Our study highlights a few practical points pertaining
to the management of LABC, including the overall treat-
ment outcome in LABC, the need for a better classifi-
cation of LABC, and the potential advantage of the RCB
index as a better endpoint to measure response.
With regard to treatment outcome, LABC contin-
ues to pose a significant clinical challenge, with stand-
ard available chemotherapy resulting in clinical and
pathologic CRs in only a very few patients. In our study,
clinical response following neoadjuvant chemotherapy
did not well predict pathologic response. Of all patients,
22% achieved pCR, a result that is essentially consistent
with other trials in LABC (mostly using standard
anthracycline–taxane combination chemotherapy) 11–14.
None of the patients in the present study with IBC
achieved pCR, indicating the aggressive—and probably
distinct—nature of this disease entity that begs for novel
treatment strategies.
The optimal treatment algorithm, schedule, and
mode of drug delivery in LABC needs to be determined.
The best outcome yet reported in a randomized phase
III trial in this patient population was obtained with
metronomic chemotherapy given in protracted low
doses 14 as reported by the Southwest Oncology Group.
More research is needed to optimize treatment strate-
gies so as to improve outcomes in LABC and IBC.
A better classification of LABC is also of paramount
significance. The general term LABC includes stage
IIIA (T0 N2; T1/2 N2; T3 N1/2), stage IIIB (T4, N0–2),
and stage IIIC (any T, N3) tumours. Some of the classi-
cal biologic prognostic factors such as size and lymph
node invasion have implications that are similar in LABC
to their implication in earlier disease stages. However,
many others differ in LABC. For example, the prognos-
tic significance for hormone receptor status and HER2/
neu is unclear. In the present study, among patients
with hormone-responsive tumours, only 19% achieved
pCR as compared with 25% for patients with ER–/PR–
tumours, indicating favourable chemosensitivity of
hormone non-responsive tumours to neoadjuvant
chemotherapy in LABC. In an evaluation of 124 pa-
tients with stage III breast cancer, Stewart and others 5
found that, among patients with inoperable tumours,
ER status had no effect on prognosis. Other studies sug-
gested that ER– tumours are more chemosensitive than
ER+ tumours are 11–15. In the present study, among
patients with HER2/neu-positive tumours, 17% achieved
pCR as compared with 25% whose tumours were HER2/
neu-negative.
The patients included in our study were treated
before the use of trastuzumab became routine in the
neoadjuvant setting. The foregoing result will there-
fore likely improve with that change in clinical practice,
FIGURE 2   Overall survival (OS) by pathologic complete response
(pCR vs. no pCR) to neoadjuvant chemotherapy in locally advanced
breast cancer.
FIGURE 3   Event-free survival (EFS) by pathologic complete response
(pCR) to neoadjuvant chemotherapy in locally advanced breast cancer.
RDB = residual disease in breast; RDBLN = residual disease in breast
and lymph nodes.RESIDUAL CANCER BURDEN AND LOCALLY ADVANCED BREAST CANCER
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as did outcomes reported in operable HER2/neu-positive
breast cancer with the addition of trastuzumab 16.
Overexpression of HER2/neu, otherwise known to be a
poor prognostic factor, was found to be a predictor of a
higher pCR with trastuzumab-based treatment 16. It is
therefore evident that reliable predictive and correla-
tive prognostic markers for outcome are essential to
the individualization and improvement of treatment
outcomes in LABC.
The search for such markers is by no means sim-
plistic. It likely requires application of optimal mo-
lecular classification methods; different combinations
of the various predictors are likely to lead to different
prognostic entities with different treatment outcomes.
Investigators at M.D. Anderson 6 and the University
of Carolina 7 independently examined chemosensi-
tivity in basal-like breast cancers, which are also
known by the clinical proxy “triple negative” (ER–,
PR–, HER2/neu-negative) 8. Clinical response to
neoadjuvant doxorubicin and cyclophosphamide was
significantly higher among basal-like (86%) than
among non-basal-like (HER2 68%, luminal 60%) breast
cancers. Similarly, pCR occurred in 30% of basal-like,
27% of HER2/neu-positive, and 13% of luminal breast
cancers 7. However, basal-like breast cancers have a
poor prognosis, which seems paradoxical given their
sensitivity to chemotherapy. The difference in outcome
appears to be a result of the more frequent early re-
lapses seen among basal-like and HER2/neu-positive
tumours that fail to achieve pCR. On the other hand,
poor prognosis reflects the fewer treatment options
available for ER–, PR–, and HER2/neu-negative tu-
mours and the intrinsic biology of this subtype, which
exhibits a high rate of relapse if complete eradication
is not achieved and a poor outcome once relapse oc-
curs 7. That understanding suggests that the basal-like
and HER2/neu subtypes that make up the preponder-
ance of ER– tumours are the tumours most affected
by improvements in chemotherapy.
Other prognostic markers that may have differ-
ent implications in LABC include tumour nuclear grade,
with poorly differentiated tumours being more likely
than well differentiated tumours to respond to
neoadjuvant chemotherapy 9,17. Also, increased ex-
pression of the human nuclear protein Ki-67, which
is associated with cell proliferation and is used in rou-
tine pathology as a “proliferation marker” to meas-
ure the growth fraction of cells in human tumours,
has been correlated with a better response to chemo-
therapy 18,19.
The main purpose of our study was to determine
the ease and practical application of the RCB index in
clinical practice as a more comprehensive and in-
formative endpoint for residual disease following
preoperative chemotherapy, based on data reported
by Symmans and his colleagues at M.D. Anderson
Cancer Center 10. The identification of reliable treat-
ment endpoints is of crucial importance. It seems
logical that a good response to chemotherapy in LABC
would predict for better long-term prognosis and ulti-
mately for survival. The achievement of a pCR has
been viewed as an acceptable primary endpoint for
outcome following neoadjuvant chemotherapy for
LABC; patients who achieve a pCR to neoadjuvant
chemotherapy for breast cancer have an improved
prognosis 4,20–23.
In our study, the achievement of a pCR was associ-
ated with better OS and EFS. The prognostic significance
of a pCR has been confirmed recently in a large pub-
lished experience including 1731 patients from M.D.
Anderson 3. However, a large trial involving 2411 pa-
tients with operable breast cancer did not show that
improving the pCR affects OS significantly. The adop-
tion of OS as a primary endpoint probably limited the
ability of that trial to demonstrate a survival benefit,
and OS may not have been an ideal endpoint because
the trial was not powered to detect such small differ-
ences in OS or in disease-free survival 15.
Despite the focus on pCR as a surrogate endpoint
in neoadjuvant trials, logic seems to suggest that non-
pCR patients may derive clinical benefit from regres-
sion of the primary tumour, even if survival is not
proved to be affected. Symmans et al. studied the con-
cept of residual cancer burden (RCB) in a study includ-
ing 432 patients with operable breast cancer who
completed neoadjuvant chemotherapy at M.D.
Anderson 10. The RCB index was a continuous predic-
tor of DRFS, and it predicted relapse more strongly than
AJCC stage did.
Our study found that RCB, defined from routine
pathology materials, was easily quantifiable and ap-
pears to be better than pCR at predicting outcome af-
ter neoadjuvant chemotherapy in LABC. Higher RCB
scores were significantly associated with lower EFS
and a trend toward a lower rate of OS. The RCB index
maintained significance as an independent predictor
of EFS in the main-effects multivariate Cox regres-
sion model. What is interesting is that, in multivariate
analysis, pCR did not maintain its significance as an
independent predictor of EFS. That result would sug-
gest that more meaningful prognostic implications
could be derived from RCB scores in patients under-
going neoadjuvant therapy.
Neither the RCB nor the pCR was statistically asso-
ciated with OS—an expected result, because of the
small number of patients and limited number of events
in the short duration of study between 2001 and 2005,
which precludes accurate OS assessment.
Prospective trials are needed to further evaluate
the role of RCB as an endpoint following primary chemo-
therapy for LABC. Because of the small number of
patients and limited number of events in each group, it
is not possible to draw definitive conclusions from the
present study. Further analyses of other databases are
required to confirm our finding of no difference in dis-
ease-free and overall survival between patients withNAHLEH et al.
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residual ductal carcinoma in situ and those with no in-
vasive or in situ disease following neoadjuvant
chemotherapy for breast cancer.
5. CONCLUSIONS
A better stratification of LABC based on specific markers
is needed. The search for reliable predictive and
correlative prognostic markers for outcome is essen-
tial to advance our understanding of this disease entity
and consequently to improve treatment outcomes. How-
ever, the identification of reliable, informative, uniform
endpoints is an essential first step that would also
strengthen confidence in the value of neoadjuvant tri-
als and anticipate the results of larger adjuvant trials.
The classification of residual disease based on various
pathologic responses may better classify the prognos-
tic groups and would help to improve and individualize
targeted treatment strategies. The RCB index, an eas-
ily quantifiable system, has the potential of providing a
uniform method for reporting pathologic response with
broad applicability.
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